Connect
MJA
MJA

Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes

Roger E Peverill
Med J Aust 2002; 176 (6): 296-297.
Published online: 18 March 2002

To the Editor: A recent editorial in the Journal attempted to define a role for angiotensin II receptor (AIIR) antagonists in patients with type 2 diabetes.1 This was in the light of recent trial evidence that these agents reduce progression to renal failure in patients with type 2 diabetes and diabetic renal disease. Unfortunately, the guidelines provided were somewhat confusing and fragmented. I believe that a simpler treatment guide can be constructed, particularly when it is emphasised that the aim in diabetes is to use agents that prevent not only renal failure but also cardiovascular events.

  • Roger E Peverill

  • Centre for Heart and Chest Research, Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC.


Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.